{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T22:45:07Z","timestamp":1785451507849,"version":"3.56.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Opioid analgesics are widely used, but their long-term neurocognitive safety, particularly concerning prenatal exposure in children, is poorly understood. This study aimed to investigate the reporting association between opioid use and learning disorders and to characterize this pharmacovigilance signal, with a focus on the pediatric population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We analyzed adverse event reports from the U.S. Food and Drug Administration\u2019s Adverse Event Reporting System (FAERS) database (2004\u20132025), with external validation performed on the EudraVigilance (EV) database. Cases were identified using the MedDRA High-Level Term \u201cLearning disorders.\u201d A multi-algorithm disproportionality analysis [reporting odds ratio (ROR), proportional reporting ratio, information component, empirical Bayes geometric mean] was performed, including an all-drug screening, age-stratification, and a detailed clinical characterization of pediatric cases (&lt;18\u00a0years).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Among 9666 reports of learning disorders in FAERS, opioids were the most prominent drug class. Oxycodone (ROR 46.79) and hydrocodone-containing products (ROR up to 62.24) showed the strongest signals. This signal was persistent across all age groups. In an in-depth analysis of 65 pediatric opioid-related cases, prenatal exposure was the most frequently reported exposure context, collectively accounting for 72.3% of cases. These pediatric cases were overwhelmingly reported by consumers or lawyers (95.4%) and frequently associated with severe outcomes like congenital anomalies (32.3%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This large-scale analysis identifies a strong and persistent signal of disproportionate reporting for learning disorders associated with opioids. In the pediatric population, these reports are frequently linked to prenatal exposure and severe outcomes. These hypothesis-generating findings highlight a potential safety concern that warrants further investigation in controlled epidemiological studies. While causality cannot be established, the results suggest the importance of cautious prescribing of opioids to women of childbearing potential and support considering neurodevelopmental follow-up for prenatally exposed children.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/js9.0000000000004502","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T15:00:18Z","timestamp":1765983618000},"page":"5635-5644","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Association between opioid analgesics and learning disorders: a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) and EudraVigilance databases"],"prefix":"10.1097","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7283-9564","authenticated-orcid":false,"given":"Zeying","family":"Feng","sequence":"first","affiliation":[{"name":"Clinical Trial Institution Office, Liuzhou Hospital of Guangzhou Women and Children\u2019s Medical Center, Liuzhou, China"},{"name":"Liuzhou Key Laboratory of Clinical Drug Research and Evaluation for Women and Children, Liuzhou Hospital of Guangzhou Women and Children\u2019s Medical Center, Liuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianting","family":"Qin","sequence":"additional","affiliation":[{"name":"Liuzhou Key Laboratory of Clinical Drug Research and Evaluation for Women and Children, Liuzhou Hospital of Guangzhou Women and Children\u2019s Medical Center, Liuzhou, China"},{"name":"Department of Clinical Pharmacy, Liuzhou Hospital of Guangzhou Women and Children\u2019s Medical Center, Liuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingmei","family":"Shi","sequence":"additional","affiliation":[{"name":"Clinical Trial Institution Office, Liuzhou Hospital of Guangzhou Women and Children\u2019s Medical Center, Liuzhou, China"},{"name":"Liuzhou Key Laboratory of Clinical Drug Research and Evaluation for Women and Children, Liuzhou Hospital of Guangzhou Women and Children\u2019s Medical Center, Liuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenjie","family":"He","sequence":"additional","affiliation":[{"name":"Clinical Trial Institution Office, Liuzhou Hospital of Guangzhou Women and Children\u2019s Medical Center, Liuzhou, China"},{"name":"Liuzhou Key Laboratory of Clinical Drug Research and Evaluation for Women and Children, Liuzhou Hospital of Guangzhou Women and Children\u2019s Medical Center, Liuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilin","family":"Lian","sequence":"additional","affiliation":[{"name":"Clinical Trial Institution Office, Liuzhou Hospital of Guangzhou Women and Children\u2019s Medical Center, Liuzhou, China"},{"name":"Liuzhou Key Laboratory of Clinical Drug Research and Evaluation for Women and Children, Liuzhou Hospital of Guangzhou Women and Children\u2019s Medical Center, Liuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Jingjing","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Liuzhou Maternity and Child Healthcare Hospital, Liuzhou, China"},{"name":"Guangxi Clinical Research Center for Obstetrics and Gynecology, Liuzhou Hospital of Guangzhou Women and Children\u2019s Medical Center, Liuzhou, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingyuan","family":"Zeng","sequence":"additional","affiliation":[{"name":"Guangxi Clinical Research Center for Obstetrics and Gynecology, Liuzhou Hospital of Guangzhou Women and Children\u2019s Medical Center, Liuzhou, Guangxi, China"},{"name":"Department of Gynecology and Obstetrics, Liuzhou Hospital, Guangzhou Women and Children\u2019s Medical Center, Liuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"R1-20260417","doi-asserted-by":"crossref","first-page":"1483\u201385","DOI":"10.1016\/S0140-6736(19)30854-2","article-title":"Optimal postoperative pain management: redefining the role for opioids","volume":"393","author":"Hollmann","year":"2019","journal-title":"Lancet"},{"key":"R2-20260417","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1002\/bjs.11477","article-title":"Acute postoperative pain management","volume":"107","author":"Small","year":"2020","journal-title":"Br J Surg"},{"key":"R3-20260417","doi-asserted-by":"crossref","first-page":"46","DOI":"10.21037\/tgh-20-188","article-title":"Enhanced recovery after surgery in children","volume":"6","author":"Rafeeqi","year":"2021","journal-title":"Transl Gastroenterol Hepatol"},{"key":"R4-20260417","doi-asserted-by":"crossref","first-page":"3\u201310","DOI":"10.4103\/joacp.JOACP_362_19","article-title":"Opioid sparing strategies for perioperative pain management other than regional anaesthesia: a narrative review","volume":"38","author":"Ghai","year":"2022","journal-title":"J Anaesthesiol Clin Pharmacol"},{"key":"R5-20260417","doi-asserted-by":"crossref","first-page":"23\u201328","DOI":"10.1007\/s40264-023-01378-1","article-title":"Cognitive safety is largely ignored in clinical drug trials: a study of registered study protocols","volume":"47","author":"Reimers","year":"2024","journal-title":"Drug Saf"},{"key":"R6-20260417","doi-asserted-by":"crossref","first-page":"4094\u2013102","DOI":"10.1097\/JS9.0000000000002435","article-title":"Safety evaluation of inotuzumab ozogamicin: a pharmacovigilance study based on the FAERS database","volume":"111","author":"Duan","year":"2025","journal-title":"Int J Surg"},{"key":"R7-20260417","doi-asserted-by":"crossref","first-page":"5105\u201321","DOI":"10.1097\/JS9.0000000000002607","article-title":"Immunotherapy-induced cholestasis in cancer: insights from the two real-world pharmacovigilance databases of FAERS and VigiBase","volume":"111","author":"Yan","year":"2025","journal-title":"Int J Surg"},{"key":"R8-20260417","first-page":"10081","article-title":"Revised strengthening the reporting of cohort, cross-sectional and case-control studies in surgery (STROCSS) guideline: an update for the age of Artificial Intelligence","volume":"2","author":"Riaz","year":"2025","journal-title":"Prem J Sci"},{"key":"R9-20260417","first-page":"10082","article-title":"Transparency in the reporting of Artificial Intelligence \u2013 the TITAN Guideline","volume":"2","author":"Riaz","year":"2025","journal-title":"Prem J Sci"},{"key":"R10-20260417","doi-asserted-by":"crossref","first-page":"1442002","DOI":"10.3389\/fphar.2024.1442002","article-title":"A disproportionality analysis of low molecular weight heparin in the overall population and in pregnancy women using the FDA adverse event reporting system (FAERS) database","volume":"15","author":"Xu","year":"2024","journal-title":"Front Pharmacol"},{"key":"R11-20260417","doi-asserted-by":"crossref","first-page":"1737\u201345","DOI":"10.1038\/s41390-025-04029-6","article-title":"Neurodevelopmental challenges at age four following fetal exposure to maternal opioid maintenance treatment","volume":"98","author":"Kanervo","year":"2025","journal-title":"Pediatr Res"},{"key":"R12-20260417","doi-asserted-by":"crossref","first-page":"e077664","DOI":"10.1136\/bmj-2023-077664","article-title":"Prenatal opioid exposure and subsequent risk of neuropsychiatric disorders in children: nationwide birth cohort study in South Korea","volume":"385","author":"Kang","year":"2024","journal-title":"BMJ"},{"key":"R13-20260417","doi-asserted-by":"crossref","first-page":"1526270","DOI":"10.3389\/fphar.2025.1526270","article-title":"Neurotoxicity mechanisms and clinical implications of six common recreational drugs","volume":"16","author":"Wang","year":"2025","journal-title":"Front Pharmacol"},{"key":"R14-20260417","doi-asserted-by":"crossref","first-page":"a039362","DOI":"10.1101\/cshperspect.a039362","article-title":"Opioid-induced molecular and cellular plasticity of ventral tegmental area dopamine neurons","volume":"11","author":"Doyle","year":"2021","journal-title":"Cold Spring Harb Perspect Med"},{"key":"R15-20260417","doi-asserted-by":"crossref","first-page":"977\u201392","DOI":"10.1038\/s41380-019-0435-z","article-title":"Hippocampal \u00b5-opioid receptors on GABAergic neurons mediate stress-induced impairment of memory retrieval","volume":"25","author":"Shi","year":"2020","journal-title":"Mol Psychiatry"},{"key":"R16-20260417","doi-asserted-by":"crossref","first-page":"e2020029074","DOI":"10.1542\/peds.2020-029074","article-title":"Neonatal opioid withdrawal syndrome","volume":"146","author":"Patrick","year":"2020","journal-title":"Pediatrics"},{"key":"R17-20260417","doi-asserted-by":"crossref","first-page":"17\u201329","DOI":"10.1016\/j.clp.2022.10.007","article-title":"Neonatal opioid withdrawal syndrome: an update on developmental outcomes","volume":"50","author":"Benninger","year":"2023","journal-title":"Clin Perinatol"},{"key":"R18-20260417","doi-asserted-by":"crossref","first-page":"142\u201346","DOI":"10.1097\/ANA.0000000000000876","article-title":"Prenatal opioid exposure and neurodevelopmental outcomes","volume":"35","author":"Lee","year":"2023","journal-title":"J Neurosurg Anesthesiol"},{"key":"R19-20260417","doi-asserted-by":"crossref","first-page":"1039055","DOI":"10.3389\/fped.2022.1039055","article-title":"The immediate and long-term effects of prenatal opioid exposure","volume":"10","author":"Yen","year":"2022","journal-title":"Front Pediatr"},{"key":"R20-20260417","doi-asserted-by":"crossref","first-page":"67\u201374","DOI":"10.1016\/j.pedn.2019.12.011","article-title":"The effects of neonatal abstinence syndrome on language delay from birth to 10 years","volume":"51","author":"Miller","year":"2020","journal-title":"J Pediatr Nurs"},{"key":"R21-20260417","doi-asserted-by":"crossref","first-page":"500\u201309","DOI":"10.1016\/S2352-4642(24)00076-2","article-title":"School performance in children with prenatal drug exposure and out-of-home care in NSW, Australia: a retrospective population-based cohort study","volume":"8","author":"Uebel","year":"2024","journal-title":"Lancet Child Adolesc Health"},{"key":"R22-20260417","doi-asserted-by":"crossref","first-page":"1069\u201379","DOI":"10.1056\/NEJMoa2309359","article-title":"Risk of autism after prenatal topiramate, valproate, or lamotrigine exposure","volume":"390","author":"Hern\u00e1ndez-D\u00edaz","year":"2024","journal-title":"N Engl J Med"},{"key":"R23-20260417","doi-asserted-by":"crossref","first-page":"568\u201377","DOI":"10.1001\/jamaneurol.2023.0674","article-title":"Prenatal exposure to antiseizure medication and incidence of childhood- and adolescence-onset psychiatric disorders","volume":"80","author":"Dreier","year":"2023","journal-title":"JAMA Neurol"},{"key":"R24-20260417","doi-asserted-by":"crossref","first-page":"e20183095","DOI":"10.1542\/peds.2018-3095","article-title":"Hearing loss with congenital cytomegalovirus infection","volume":"144","author":"Foulon","year":"2019","journal-title":"Pediatrics"},{"key":"R25-20260417","doi-asserted-by":"crossref","first-page":"e209279","DOI":"10.1212\/WNL.0000000000209279","article-title":"Teratogenesis, perinatal, and neurodevelopmental outcomes after in utero exposure to antiseizure medication: practice guideline from the AAN, AES, and SMFM","volume":"102","author":"Pack","year":"2024","journal-title":"Neurology"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000004502","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T11:05:56Z","timestamp":1776423956000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000004502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000004502","relation":{},"ISSN":["1743-9159"],"issn-type":[{"value":"1743-9159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]},"assertion":[{"value":"2025-09-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}